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Spinocerebellar ataxia type 1 (SCA1), due to an unstable polyglutamine expansion within the 
ubiquitously expressed Ataxin-1 protein, leads to the premature degeneration of Purkinje cells 
(PCs), decreasing motor coordination and causing death within 10-15 years of diagnosis. 
Currently, there are no therapies available to slow down disease progression. As secondary 
cellular impairments contributing to SCA1 progression are poorly understood, here, we focused 
on identifying those processes by performing a PC specific proteome profiling of Sca1154Q/2Q 
mice at a symptomatic stage. Mass spectrometry analysis revealed prominent alterations in 
mitochondrial proteins. Immunohistochemical and serial block-face scanning electron 
microscopy analyses confirmed that PCs underwent age-dependent alterations in mitochondrial 
morphology. Moreover, colorimetric assays demonstrated impairment of the electron transport 
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chain complexes (ETC) and decrease in ATPase activity. Subsequently, we examined whether 
the mitochondria-targeted antioxidant MitoQ could restore mitochondrial dysfunction and prevent 
SCA1-associated pathology in Sca1154Q/2Q mice. MitoQ treatment both presymptomatically and 
when symptoms were evident ameliorated mitochondrial morphology and restored the activities 
of the ETC complexes. Notably, MitoQ slowed down the appearance of SCA1-linked 
neuropathology such as lack of motor coordination as well as preventing oxidative stress-
induced DNA / RNA damage and PC loss. Our work identifies a central role for mitochondria in 
PC degeneration in SCA1 and provides evidence for the supportive use of mitochondria-targeted 
therapeutics in slowing down disease progression. 
 
Keywords, Spinocerebellar ataxia type 1, Purkinje cells, mitochondria, oxidative stress, Electron 
transport chain (ETC) activities, neurodegeneration, antioxidant MitoQ. 
 
Introduction 
Spinocerebellar ataxia type 1 (SCA1) belongs to one of the major groups of autosomal dominant 
hereditary cerebellar ataxia. It is a fatal cerebellum-associated neurodegenerative disease (ND) 
where patients manifest their first symptoms in their mid-30s to 40s and die within 10-15 years of 
diagnosis (Burk et al., 1996). The disease is associated with an unstable trinucleotide CAG 
repeat expansion in the open reading frame of the ataxin-1 gene. This specific CAG repeat 
expansion leads to the expression of an expanded polyglutamine (polyQ) tract in the mutant 
Ataxin-1 protein (ATXN1), thereby acquiring a toxic gain-of-function property (Orr, 2012; Zoghbi, 
1995; Zoghbi and Orr, 1995, 2009). Similar to other polyQ related SCAs, pathological hallmarks 
of SCA1 involves premature degeneration of Purkinje cell (PC) dendrites, dendritic spines and 
PC soma that lead to motor incoordination, gait disorder, ataxia, dysarthria, dysphagia and 
massive cerebellar atrophy (Burk et al., 1996; Koeppen, 1991; Zoghbi and Orr, 2009). Several 
mutant SCA1 transgenic mouse models, which reliably replicate human pathology, have been 
generated and those mice have facilitated the understanding of disease mechanisms that may 
be involved in the development of the pathology. Knock-in mice harboring 154 CAG repeats in 
the ataxin-1 locus (Sca1154Q/2Q) (Watase et al., 2002) and transgenic mice that overexpress a 
mutant ATXN1 form with 82 CAG repeats selectively within PCs (B05[82Q]) (Burright et al., 
1995) have been used in the past to understand the physiological role of ATXN1 as well as 
SCA1-associated pathomechanisms. Interestingly, it was also revealed that the overexpression 
of the normal form of ATXN1, produces similar toxic effects (Fernandez-Funez et al., 2000), 
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suggesting that an activity or interaction of ATXN1 in excess is sufficient to cause neuronal 
dysfunction. 
NDs are an ever increasing socio-economic burden to the developed world. Despite substantial 
efforts in recent decades to understand mechanisms that determine the disease process in ND, 
no therapy is available to halt their progression and the only treatment option is to subdue 
symptoms. Currently, there is an urgent need for the development of valid therapies to slow 
down or stop neuronal degeneration thereby providing a better quality of life to patients. This 
lack of therapies is due at least in part to a substantial lacuna in our understanding of the early 
disease mechanisms.  
A well accepted and conserved feature of all neurons that degenerate is that they have an 
exceptional demand for energy in order to maintain their membrane potential and generate an 
action potential (Calabrese et al., 2001; Schapira, 1998). Because of their limited glycolytic 
capacity, neurons are highly dependent on aerobic oxidative phosphorylation (OXPHOS) which 
is fulfilled by mitochondria located at strategic sites inside the cell and synapse. On the other 
hand, the OXPHOS machinery is a major producer of reactive oxygen species (ROS) which 
cause oxidative damage to DNA, RNA, lipids and proteins (Beal, 1996; Manfredi and Beal, 2000; 
Schapira, 1996). Hence, a fine-tuned regulation of OXPHOS activity and protective mechanisms 
against ROS including antioxidants is essential to maintain a healthy balance between energy- 
and ROS production. Therefore, it is not surprising that mitochondrial dysfunction and oxidative 
stress have been implicated in various NDs (Burte et al., 2015; Chaturvedi and Flint Beal, 2013; 
Karbowski and Neutzner, 2012), such as Alzheimer's disease (AD) (Friedland-Leuner et al., 
2014; Simoncini et al., 2015), Parkinson's disease (PD) (Haelterman et al., 2014; Hang et al., 
2015; Overk and Masliah, 2014; Ryan et al., 2015), Huntington's disease (HD) (Ayala-Pena, 
2013; Guedes-Dias et al., 2015; Labbadia and Morimoto, 2013; Tsunemi and La Spada, 2012) 
and Amyotrophic lateral sclerosis (ALS) (Cozzolino et al., 2013; Duffy et al., 2011; Magrane and 
Manfredi, 2009). Importantly, in inherited recessive ataxias such as Autosomal recessive spastic 
ataxia of Charlevoix-Saguenay (ARSACS) or Friedreich's ataxia, mutations within mitochondria-
associated proteins are the most frequent cause underlying the development of these disease 
(Calabrese et al., 2005; Criscuolo et al., 2015; Girard et al., 2012). These observations are not 
unexpected considering that PCs are amongst the most active neurons in the central nervous 
system and have a high energy demand that makes them particularly susceptible to 
mitochondrial impairment or dysfunction (Zeviani et al., 2012). Importantly, a recent study 
revealed that mutant ATXN1 mediates the reduction or inhibition of the high-mobility group box 1 
protein (HMGB1) in mitochondria, which led to increased mitochondrial DNA damage in a SCA1 
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mouse model. Mitochondrial DNA damage, as well as neuropathology and a motor deficit could 
be rescued by viral-mediated over-expression of HMGB1 (Ito et al., 2015). However, it remained 
unclear when during disease progression mitochondria became functionally altered, what 
precise mitochondrial processes were impaired and whether those impairments contributed to 
SCA1 pathology.  
Here, we focused on identifying processes which are specifically impaired during the 
appearance of SCA1-associated symptoms and contribute to disease progression. PC specific 
proteome profiling of Sca1154Q/2Q mice revealed prominent alterations in mitochondrial proteins 
which coincided with the symptomatic phase of the disease. Targeting mitochondrial 
impairments by treating Sca1154Q/2Q mice with a mitochondria- targeted antioxidant; MitoQ 




Heterozygous B6.129S-Atxn1tm1Hzo/J (Sca1154Q/2Q) mice were obtained from Jackson 
Laboratory (Watase et al., 2002). Animal care, housing, ethical usage and procedure were in 
accordance with the Swiss Veterinary Law guidelines. 
MitoQ treatment 
500 μM MitoQ (in the form of MS010, MitoQ mesylate adsorbed to β-cyclodextrin) in drinking 
water was provided to wild type (WT) and Sca1154Q/2Q mice ad libitum for either 16 weeks (long 
term treatment; P40-P150) or for 3 weeks (short term treatment; P90-P110), whereas control 
mice were supplied with drinking water alone. Fresh MitoQ solution was applied twice a week.  
Chromium treatment 
Oxidative stress in mouse brain was induced as previously described (Travacio et al., 2000). In 
short, 25 mg/kg per day potassium dichromate (Chromium(VI); Merck) was applied in drinking 
water for 3 days. 
Laser-Capture Microdissection (LCM) and Mass spectrometry (MS) analysis 
LCM was performed as previously described (Ruegsegger et al., 2016). Mice were sacrificed by 
cervical dislocation. Cerebella were removed, embedded in O.C.T compound (Tissue TEK) and 
frozen on dry ice. 15 µm thick sections were cut by a cryostat, transferred onto membrane slides 
(membrane Slide 1.0 PET, Zeiss) and kept at -80°C. Prior to LCM, slides were thawed, stained 
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with Toluidine blue (0.1% Toluidine blue in PBS), rinsed in 70% and 100% ethanol (ETOH) and 
dried at room temperature (RT). LCM was performed using the PALM microBeam system 
(Zeiss). Areas of 3’000’000 µm2 for PCs and 2’000’000 µm2 for GCs were collected and moved 
into capture tube caps (AdhesiveCap 500 opaque, Zeiss). Proteins were extracted in 10 µl RIPA 
buffer after cell lysis. Tubes were centrifuged for 10 min at 16’000 x g (4°C) and stored at -80°C 
until MS. 
MS was performed as previously described (Ruegsegger et al., 2016). Samples were loaded on 
a 12% SDS-gel and run to a distance of 1 cm. After staining the gel for 2 h in InstantBlue 
(Expedeon), lanes were cut into 10 bands, and each band into 4 pieces. Pieces were destained 
for 20 min in 30% ETOH, 30 min in 100% ETOH and washed 30 min in ddH2O (cycle repeated 
thrice). Shotgun LCMS/MS was performed at the MS and Proteomics Core Facility of the 
Department of Clinical Research, University of Bern. Samples were measured 3x using a 
spectrum sampling approach and the MaxQuant software was used to assess the protein 
abundance (Heller et al., 2007). Only proteins with at least 3 or more unique peptides, having a 
PMSS higher than 30 and showing 2-fold changes were used for analysis. 
Immunohistochemistry (IHC) 
Mice were injected with 6 mg/kg anesthesia solution (24% Ketasol (Graeub), 16% Xylasol 
(Graeub), 60% NaCl solution 0.9% (Merck)) and intracardially perfused with 4% 
paraformaldehyde (PFA) in 0.1M PBS, pH = 7.4. Isolated cerebella were post-fixed overnight in 
4% PFA and soaked for at least 24 h in 30% sucrose (in PBS, pH = 7.4). Sagittal 50 µm thick 
sections were cut with a cryostat and stored in 0.8% sodium-azide solution (in PBS, pH = 7.4). 
Sections were blocked in buffered 3% bovine serum albumin (BSA; Roche) for 2 h at RT 
followed by incubation in primary antibody (AB) solution (appropriate ABs, 3% BSA, 0.3% Triton 
X-100 in PBS, pH = 7.4) at 4°C for 2 days on a shaker. Section were washed 3x 30 min in 
washing solution (0.1% Triton X-100 in PBS, pH = 7.4) and incubated in secondary AB solution 
(appropriate ABs, 3% BSA, 0.3% Triton X-100 in PBS, pH = 7.4) over night at 4°C or 6 h at RT 
respectively. Section were washed again 3x 20 min in washing solution before they were 
mounted and coverslipped using mowiol mounting media. Following dilutions of antibodies were 
used: mouse anti-Calbindin, 1:1000 (ab82812, Abcam), rabbit anti-Calbindin, 1:1000 (ab11426, 
Abcam), mouse anti-8-hydroxy-guanosine (8-OHdG), 1:500 (ab62623, Abcam), goat anti-
HSP60, 1:500 (sc-1052, Santa Cruz Biotechnology), secondary AB - Alexa Fluor conjugate, 
1:1000 (Invitrogen). IHC using the goat anti-HSP60 AB required antigen retrieval prior to the 
blocking step. Sections were incubated for 20 min at 85°C in sodium citrate buffer (10 mM 
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dehydrate tri-sodium citrate (Merck), 0.05% Tween 20 (Merck) in ddH2O, pH 6.0) and washed 2x 
5 min in PBS. 
Confocal Microscopy and Image analysis 
All images were taken from lobule IX or at the primary fissure (only for PC cell number counting) 
with a confocal laser-scanning microscope Leica TCS SP8 (Leica Microsystem) or an Olympus 
Fluoview 1000-BX61 (Olympus, Tokyo).  
Mitochondrial morphology analysis was assessed with 3D image analysis software Imaris 7.6 
(Bitplane): Isosurfaces were generated for HSP60 intensities selectively within PC somas. 
Sphericity values of isosurfaces were exported for subsequent analysis. (1) Pooled data was 
plotted as histogram in order to display the distribution of mitochondria according to their shape. 
(2) Percentages of mitochondria falling below or above a reference value (median sphericity 
from age-matched WT control mice) were measured and used for statistical analysis. 8-OHdG 
intensities within PC somas (excluding nucleus) were measured using Fiji software. PC number 
was quantified in lobule V at the primary fissure over a distance of 315 µm as previously 
described (Ruegsegger et al., 2016). The plot profile of Fiji was used to quantify the Calbindin 
fluorescence intensity profile from the perikaryon center over the molecular layer as previously 
described (Watase et al., 2002). The profiles of different sections of age-matched mice were 
averaged and plotted. 
Electron microscopy analysis 
Anesthetized mice were intracardially perfused first with 0.1 M PBS (pH = 7.4) for 1 min and 
then fixed for 25 min with fixation solution (2.5% glutaraldehyde (GA) + 2% PFA in 0.1 M Na-
cacodylate, pH = 7.4) at a speed of 8 ml/min. Cerebella were isolated 2 h after perfusion and 
post-fixed overnight at 4°C in fixation solution. 180 µm sagittal sections were cut with a 
vibratome. Bloc staining, dehydration and embedding were performed as previously described 
(Deerinck et al., 2010) with following modification: post-fixation was done in 0.15 M cacodylate 
buffer, 1.5% potassium ferrocyanide and 2% osmium tetroxide. Sample blocs were mounted on 
aluminium specimen pins (Gatan, Pleasonton, CA, USA) with a conductive silver epoxy glue. 
After a minimum of drying time of 4 h the blocs were imaged at the SBF-SEM using a Quanta 
FEG 250 (FEI, Eindhoven, The Netherlands), equipped with a Gatan 3View2XP in-situ 
ultramicrotome (Gatan). Images were recorded at 3.5 kV accelerating voltage in high vacuum. 
Pixel size was set to 12 nm and the slice thickness was set to values between 50 and 100 nm. 
Image rendering was done in UCSF Chimera (Pettersen et al., 2004) and mitochondrial length 
analysis in IMOD (Kremer et al., 1996).  
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Colorimetric measurements of ETC complexes: I, II, IV and V activities 
Mice were sacrificed and cerebella were removed, embedded in O.C.T compound and frozen on 
dry ice. 14 µm thick, serial sections were cut by a cryostat and transferred onto an adhesive 
glass slide (LLG Labware). Sections were incubated for 40 min at 37°C in freshly prepared 
appropriate complex histochemistry media: (1) Complex I: 1.23 mg/ml (1.5 mM) Nitroblue 
tetrazolium (NBT; N6876, Sigma) and 0.625 mg/ml NADH (N8129, Sigma) were mixed in PBS, 
pH = 7.4 (adapted from (De Paepe et al., 2009). (2) Complex II: 1.23 mg/ml (1.5 mM) NBT, 
35.12 mg/ml (130 mM) sodium succinate (S2378, Sigma), 0.0613 mg/ml (0.2 mM) Phenazine 
methosulfate (PMS; P9625, Sigma) and 0.065 mg/ml (1 mM) sodium azide (S8032, Sigma) were 
mixed  in PBS (adapted from (Ross, 2011)). (3) Complex IV: 0.5 mg/ml 3,3’-diaminobenzidine 
Tetrahydrochloride (DAB; D7304, Sigma), 1 mg/ml cytochrome c (C2506, Sigma) and 
approximately 2 μg/ml (a few crystals) bovine catalase (C9322, Sigma) were mixed in PBS, pH = 
7.4 (adapted from (Ross, 2011)). (4) A total of 100 ml complex V staining media contained 50 
mg ATP (A2383, Sigma), 35.2 mg 2,4-dinitrophenol (D198501, Sigma), 40 ml 0.2 M Tris maleate 
buffer (0.2 M Tris Base, 0.2 M Maleic acid (M1296, Sigma), pH = 7.4), 6 ml 0.06 M lead nitrate 
(11520, Sigma), 10 ml 0.05 M magnesium chloride (Merck) and 44 ml ddH2O. Following the 
incubation in complex V media, sections were washed 2x in PBS and incubated for 1 min at RT 
in 1% ammonium sulfide (adapted from (Karnes et al., 2010)). Subsequent to the staining of 
each complex, sections were washed 3x 10 min in PBS before they were dehydrated for 4 min in 
70% ETOH, 4 min in 96% ETOH, 10 min in 100% ETOH and 10 min in Xylol and immediately 
mounted with Eukitt. 100x images were acquired with Nikon Eclipse E600 microscope using an 
Axiocam MRc 5 camera (Zeiss). Fiji software was used to measure intensity within PC soma. 
Behavior assays 
Motor coordination was assessed during the afternoon (2 - 6 pm) using a rotarod apparatus 
(Ugo Basile Biological Research Apparatus, Varese, Italy). The rotating speed was linearly 
increasing from 4 to 40 rpm in 300 s intervals. Mice were tested from P40-P150 once per week 
and scored for their latency to fall (in seconds). Each animal had to perform 4 trials per testing 
day with breaks of at least 10 min in between. The mean of the best 3 trials (per animal) was 
calculated and used for further analysis.   
Hind limb clasping procedure was adapted from (Gennarino et al., 2015). Mice were clinched at 
the base of the tail and lifted away from objects for maximal 30 s. Hind limb positions were 
scored as follow: “0” if the hind limbs were totally opened away from the abdomen, “1” if only one 
hind limb was retracted close to the abdomen for more than 10 s, “2” if both hind limbs were 
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retracted close to the abdomen for more than 10 s, “3” if both hind limbs were more than 80% 
retracted and nearly touched the abdomen and “4” if both hind limbs were fully retracted and 
touched the abdomen. 
Statistical Analysis 
At least 3 biological replicates of every age-matched group were used for statistical analysis. 
Statistical significance was calculated with GraphPadPrism 5 and values are presented as mean 
± standard error of the mean (SEM) or as box and whiskers (Turkey). 
 
Results 
PC specific proteome analysis reveals mitochondrial alterations at symptomatic stage of 
disease 
Here, we focused on identifying PC specific cellular processes which would be altered at the 
symptomatic stage of disease and could contribute to the progression of the disease. As we 
have described previously (Ruegsegger et al., 2016), we laser dissected groups of PCs from the 
most affected cerebellar lobules VIII-X from P100, WT and Sca1154Q/2Q mice and analyzed the 
PC proteome by mass spectrometry. In a first set of experiments nearly 400 proteins were 
detected and shared between both genotypes. Only proteins with a minimum PMSS (Protein 
Match Score Summation) of 30 and for which 3 or more unique peptides had been identified, 
were taken as validly expressed. Of the 366 proteins reliably detected from two separate 
experiments, nearly 41% of the proteins displayed consistent alterations in expression levels in 
Sca1154Q/2Q PCs (Fig. 1A). This semi-quantitative analysis based on Protein Match Summation 
Score (PMSS) revealed an altered proteome; 27 proteins were upregulated and 124 were 
downregulated by at least two-fold. PANTHER (Protein ANalysis THrough Evolutionary 
Relationships) revealed an over-representation of altered proteins belonging to diverse cellular 
pathways and classes such as ATP synthesis, synaptic vesicle trafficking and glycolysis (Fig. 
1B). Interestingly, 33% of the mutant PC proteome was down-regulated and protein classes 
such as oxidoreductases and nucleic acid binding were significantly overrepresented (Fig. 1C).  
In particular, the majority of detected proteins involved in ATP synthesis and oxidoreductase 
activity were reduced in expression in Sca1154Q/2Q PCs. These included cytochrome c, ATP 
synthase subunit beta and ATP synthase subunit alpha (Fig. 1D). Additionally, several 
mitochondrial enzymes possessing oxidoreductase activity such as thioredoxin-dependent 
peroxide reductase, mitochondrial cytochrome c oxidase subunit 5A, mitochondrial NADH 
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dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13, NADH dehydrogenase 
[ubiquinone] flavoprotein 2, mitochondrial cytochrome b-c1 complex subunit 6, mitochondrial 
cytochrome c oxidase subunit 6B1 were significantly reduced in the Sca1154Q/2Q PC cells (Fig. 
1E). The extensive mitochondria-specific proteome alterations hinted towards impairment of 
mitochondrial function. Moreover, we had identified previously that at an early presymptomatic 
stage, around 4 weeks after birth, mutant PCs exhibited significant overrepresentation for 
alterations associated with synaptic and calcium binding protein classes, but not with 
mitochondrial proteins (Ruegsegger et al., 2016). In view of those findings, the detection of 
significant alterations in mitochondria-associated proteins at later symptomatic stages of 
disease, suggested that mitochondrial alterations might appear gradually, coinciding with the 
symptomatic phase of the disease and synergistically contribute to disease progression. For the 
complete list of altered proteins see Table S1. 
Age-dependent alterations in mitochondrial morphology in Sca1154Q/2Q mice 
Based on the proteomic data at P100, we next examined whether mitochondria themselves 
exhibited age-dependent alterations in mutant PCs. Using HSP60 as a mitochondrial marker, 
immunostaining of cerebellar sections at various ages revealed that HSP60 immunopositive 
mitochondria appeared more vesicular and condensed with increasing age in Calbindin positive 
PCs of Sca1154Q/2Q mice (Fig. 2A). Interestingly, at P60 mutant PCs exhibited a nearly normal 
mitochondrial morphology compared to those observed in the WT mice, however from P110 
onwards, Sca1154Q/2Q PCs presented visible and sustained alterations in mitochondrial 
morphology. In order to obtain a quantitative measure for the observed changes in mitochondrial 
shape, we generated 3D-isosurface for individual mitochondria within PCs and measured their 
sphericity (Suppl. Fig. 1). A histogram plotted for sphericity, where larger values, closer to 1.0, 
indicate a more spherical or vesicular structure, whereas smaller values indicate a more tubular 
structure, revealed that P110 WT mitochondria were enriched for smaller values as compared to 
mutant mitochondria. Notably, P110 Sca1154Q/2Q mitochondria distributed in higher numbers 
towards values closer to 1.0 compared to WT, suggesting that as the disease progressed the 
mitochondria acquired an altered, more vesicular morphology. To obtain quantitative significance 
for the observed differences, the percentage of mitochondria falling below (tubular) or above 
(vesicular) a critical sphericity value (i.e. the median value for the WT mice) were measured at 
three different ages; P60, P110 and P150. While in WT mice the ratio between tubular versus 
vesicular mitochondria was 50% at all ages, these ratios were significantly altered in Sca1154Q/2Q 
PCs. These analyses confirmed that a proportion of mitochondria in mutant PCs from P110 
onwards were morphologically altered and were more vesicular in shape (Fig. 2B). 
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Subsequently, ultrastructural analysis of mitochondria in PCs was performed by serial block-face 
scanning electron microscopy (SBF-SEM) and 3D-reconstruction of the images (Fig. 2C). The 
sketch indicates a representative spread of mitochondria in WT and mutant PCs. Note the 
presence of more tubular interlinked and elongated mitochondria in WT and the rather sparse, 
fragmented and short mitochondria present in mutant P150 Sca1154Q/2Q PCs. Measurement of 
the mitochondrial length in individual PCs further confirmed that in mutant PCs shorter 
mitochondria were dominant. Quantitative analysis demonstrated that 69% of mitochondria in 
Sca1154Q/2Q PCs fall below the median length of the WT mitochondria. Moreover, nearly 48% of 
mitochondria ranged in length from 1-1499 nm in mutant PCs, whereas in WT this was about 
31%, demonstrating that mutant PCs have altered mitochondrial morphology (Fig. 2D). 
Electron transport chain (ETC) deficits in mitochondria parallel changes in mitochondrial 
morphology in Sca1154Q/2Q PCs 
After having established that morphological impairment to mitochondria appear at around the 
same time as the disease symptoms, but are absent at earlier ages, we next examined whether 
these alterations correlated with a deficit in mitochondrial function. Since, the primary function of 
mitochondria is energy production in the form of an elevated ATP/ADP ratio, we focused on 
assessing whether deficits in ETC function and ATP production were observed in mutant PCs. 
To this end, we used a colorimetric assay to assess Complex I, II, IV and V activity in WT and 
Sca1154Q/2Q PCs. Complex I activity was measured via the NADH dehydrogenase catalysed 
redox reaction in which NADH was oxidized and nitroblue tetrazolium (NBT) was reduced. The 
blue colour so formed due to NBT reduction directly correlates with the amount of endogenous 
NADH dehydrogenase activity present within PCs and was specifically and significantly reduced 
at P110 in Sca1154Q/2Q PCs as compared to WT PCs (Fig. 3A). Interestingly, areas outside the 
PCs such as the granule cell layer (GL) and molecular layer (ML) did not display any differences 
in the NBT intensity, suggesting that Complex I activity reduction was restricted to regions-
associated with disease vulnerable PCs. Similarly, measurement of Complex II activity via 
succinate dehydrogenase revealed a statistically significant decline in activity in Sca1154Q/2Q PCs 
(Fig. 3B). Subsequently, we analyzed the activity of Complex IV by measuring the intensity of 
cytochrome c oxidation, which is detected by the brown coloring produced by the oxidation of 
diaminobenzidine (DAB), and also  found reduced Complex IV activity in P110 in Sca1154Q/2Q 
PCs compared to WT PCs (Fig. 3C). Lastly, we measured mitochondrial ATP synthase activity 
by complex V. This enzyme consumes energy stored in the proton electrochemical potential 
gradient across the membrane to generate ATP from ADP and phosphate. The resultant brown 
coloring due to formation of brown lead sulfide from ammonium sulfide in the colorimetric 
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reaction quantitatively correlates with mitochondrial ATP synthase activity. As with previous 
observations Complex V levels were diminished in mutant PCs providing evidence for reduced 
ATP production. Taken together, these experiments demonstrated that ETC complex activity as 
well as ATP production is impaired in Sca1154Q/2Q PCs at symptoms (Fig. 3D). 
Symptomatic appearance of oxidative stress induced DNA damage coincides with 
mitochondrial deficits 
As mitochondria contributes to many cellular processes such as ATP synthesis, ROS 
production, synaptic transmission, calcium homeostasis, and apoptosis, the compromised 
physiological function of mitochondria in Sca1154Q/2Q PCs would adversely affect those critical 
processes. The gradual appearance of mitochondrial dysfunction in Sca1154Q/2Q PCs at the stage 
when symptoms become evident hinted that a mitochondria-specific stressor might be involved 
in the observed impairment, therefore we focused on oxidative stress as a likely form of damage. 
Firstly, we verified whether chromium-induced oxidative stress leads to morphological alterations 
in WT PCs. A three day chromium treatment regime was performed at P110, an age where in 
the mutant condition mitochondrial changes are observed. This treatment led to the appearance 
of vesicular- shaped and fragmented mitochondria in WT PCs, suggesting that oxidative stress 
might also alter mitochondrial morphology in the disease model (Fig. 4A). To further confirm that 
the appearance of oxidative stress at a particular stage in disease correlates with the functional 
mitochondrial alterations, we measured ETC complexes in WT mice after three day chromium 
treatment regime. This treatment led to a conspicuous reduction in the activity of Complexes I 
and IV, thereby mimicking the impairments observed in mutant PCs (Fig. 4B).  
As oxidative stress induces DNA damage including mitochondrial DNA damage, an antibody 
against the oxidative DNA damage biomarker; 8-hydroxy-2'-deoxyguanosine (8-OHdG) was 
applied to cerebellar sections from both genotypes at P60 (early symptomatic stage), P110 
(symptomatic stage) and P150 (late symptomatic stage) of disease. At P60, low and equal 
amounts of immunoreactivity of 8-OHdG was observed in both genotypes (Fig. 4C). However, 
by P110, enhanced 8-OHdG immunoreactivity was observed selectively in Sca1154Q/2Q PCs, 
whereas in WT PCs 8-OHdG immunoreactivity remained nearly unchanged from that measured 
at P60. At P150, the intensity of 8-OHdG immunolabeling was significantly increased in 
Sca1154Q/2Q PCs, indicating that oxidative stress induced DNA damage was present in mutant 
PCs at symptomatic stages (Fig. 4D). Altered mitochondrial morphology associated with 
oxidative stress and the corresponding evidence for DNA damage in mutant PCs at P110 but not 
12 
 
at P60 further strengthened our observation that mitochondrial impairments appear gradually 
during the symptomatic stage of the disease and are absent at early presymptomatic stages. 
Administration of the mitochondria-targeted antioxidant MitoQ improves mitochondrial 
morphology 
Our observation that the appearance of enhanced oxidative stress correlates with impaired 
mitochondrial morphology and functioning raised the question whether reduction in oxidative 
damage might improve observed mitochondrial deficits present specifically within Sca1154Q/2Q 
PCs. To this end, we decided to treat mice with MitoQ (mitoquinone mesylate: [10-(4,5-
dimethoxy-2-methyl-3,6-dioxo-1,4-cycloheexadienlyl) decyl triphenylphosphonium 
methanesulfonate]), which is a mitochondria-targeted antioxidant that specifically accumulates 
within the mitochondria in vivo and moreover, no deleterious side effects or pro-oxidative 
properties have been found after long term treatment with the levels of MitoQ we use 
(Rodriguez-Cuenca et al., 2010). Firstly, we started the administration of MitoQ at P40, an early 
age before mitochondrial changes are observed. The treatment was continued until P150, an 
age corresponding to a late stage of the disease, where mitochondrial impairments are present 
in Sca1154Q/2Q PCs. Examining mitochondrial morphology at P150 revealed that WT mice did not 
show any significant alterations after MitoQ, treatment, although there was a trend towards a 
slight increase in the ratio between tubular mitochondria versus vesicular mitochondria. Notably, 
MitoQ administration to Sca1154Q/2Q mice for more than hundred days significantly delayed the 
appearance of alterations in mitochondrial morphology and the ratio between tubular and 
vesicular mitochondria remained closer to those observed in WT conditions (Fig. 5A-B).  
Subsequently, we administered MitoQ at ages when morphological alterations to mitochondria 
were already present in order to examine whether MitoQ could now ameliorate existing 
alterations. Short-term MitoQ treatment from P90 to P110 in Sca1154Q/2Q mice was sufficient to 
reduce the percentage of vesicular shaped mitochondria to amounts similar to those observed in 
WT PCs (Fig. 5C-D), demonstrating that oxidative stress is involved in symptomatic 
mitochondria-associated alterations in SCA1. Lastly, we performed an ultrastructural analysis of 
mitochondria in PCs by serial block-face scanning electron microscopy (SBF-SEM) and 3D-
reconstruction of the images. Here, we treated mice with MitoQ from P90 to P110 and the length 
of the reconstructed mitochondria was measured. As previously observed via 
immunohistochemistry, ultrastructural analysis also revealed a shift in the distribution of 
Sca1154Q/2Q mitochondria from shorter to longer lengths after MitoQ treatment, suggestive of a 
correlation between levels of oxidative stress and mitochondrial morphology (Fig. 5E-F). 
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MitoQ treatment restores mitochondrial function in Sca1154Q/2Q PCs  
Next, we examined whether MitoQ treatment would have the potential to completely inhibit or 
slow down the deficits in ETC and ATP production which were observed in mutant PCs. After 
chronically treating mutant and WT mice with MitoQ (P40-P150), we assessed the activity of 
Complexes I, II, IV and V in WT and Sca1154Q/2Q PCs. Complex I activity revealed that in MitoQ 
treated Sca1154Q/2Q PCs, this activity was restored to similar levels as those observed in WT 
condition. While significant reduction in Complex I activity was observed between WT and 
Sca1154Q/2Q PCs at P150, no difference was observed between P150, WT and MitoQ treated 
Sca1154Q/2Q PCs, indicating that the antioxidant MitoQ was effective in inhibiting or delaying ETC 
complex impairments (Fig. 6A). Similarly, measurement of the Complex II activity via succinate 
dehydrogenase revealed a statistically significant increase in activity in MitoQ treated Sca1154Q/2Q 
PCs (Fig. 6B). We further analyzed the activity of Complex IV and as with the other complexes 
of the ETC found near normal levels of Complex IV activity in MitoQ treated Sca1154Q/2Q PCs 
(Fig. 6C). Finally, we measured mitochondrial ATP synthase activity and yet again found normal 
levels of Complex V activity in MitoQ treated mutant PCs (Fig. 6D).  
In these experiments Sca1154Q/2Q mice were chronically treated with MitoQ from an early 
symptomatic stage, therefore we next specifically evaluated whether a short MitoQ treatment in 
mutant mice at a stage, when mitochondrial impairments are already present, would have a 
beneficial effect. Treating mice with MitoQ for twenty days from p90-P110 revealed that all ETC 
complex activities were restored to near WT levels (Suppl. Fig. 2A-D). Moreover, 8-OHdG 
immunoreactivity was restored to WT levels in Sca1154Q/2Q PCs (Suppl. Fig. 2E), indicating that 
even short duration of MitoQ treatment after symptoms were established was sufficient to 
restore mitochondrial functioning. 
MitoQ administration ameliorates SCA1-associated pathology in Sca1154Q/2Q mice 
We next assessed whether the amelioration in mitochondrial morphology and functionality by 
MitoQ could also positively impact SCA1-linked pathological features such as impaired motor 
coordination, gait imbalance and hind-limb clasping. Notably, while Sca1154Q/2Q mice from P50 
onwards, exhibited a gradual decline in rotarod performance, MitoQ treated Sca1154Q/2Q mice 
remained consistently stable from P90 onwards. With increasing age the performance of 
Sca1154Q/2Q mice on the rotarod significantly diminished compared to those of MitoQ treated 
Sca1154Q/2Q mice, which remained consistently stable and significantly higher compared to the 
mutant mice at all stages of the disease (Fig. 7A). Interestingly, WT MitoQ treated mice also 
exhibited a slight improvement in motor coordination as compared to untreated WT control mice 
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(Fig. 7A). Furthermore, clasping of hind-limbs was significantly reduced in Sca1154Q/2Q MitoQ 
treated mice compared to untreated littermates and this was already visible after 70 days of 
MitoQ treatment (Fig. 7B). 
Additionally, we examined the impact of MitoQ treatment on SCA1-associated cellular alterations 
such as decline in Calbindin expression levels correlating with the degeneration of PC spines 
and the loss of PCs. Measurement of expression intensities for Calbindin from the perikaryon 
center along the dendrites revealed that PCs from P150 Sca1154Q/2Q mice which had been 
treated with MitoQ from P40 onwards had higher Calbindin expression levels than PCs from 
untreated Sca1154Q/2Q mice of the same age, indicative of sustained PC functioning (Fig. 7C). 
Calbindin labeling intensities were slightly higher in PCs from Sca1154Q/2Q at P110, where MitoQ 
treatment had been initiated after mitochondrial impairments were evident and only for a short 
duration of 20 days (Fig. 7C). Subsequently, counting of PCs at P150 after chronic MitoQ 
treatment revealed unchanged PC numbers in MitoQ treated mutant PCs compared to WT mice, 
whereas reduced PC numbers, suggestive of PC degeneration, were observed in Sca1154Q/2Q 
cerebellum (Fig. 7D). A similar positive effect of MitoQ on PC numbers was also observed at 
P110 when the mice had been treated with MitoQ for a short period of time, highlighting the 




This study was initiated to identify SCA1-associated alterations that would influence disease 
progression and related symptoms. To this end, we performed a PC-specific proteome analysis 
of mutant Sca1154Q/2Q mice at P100, when symptoms are evident. This approach revealed an 
accumulation of mitochondrial alterations in mutant PCs compared to WT. Interestingly, in our 
previous study using similar approaches at presymptomatic stages, we identified significant 
enrichment for synaptic alterations in mutant PCs immediately after cerebellar maturation. 
Moreover, expression changes in the synaptic proteome involving the PC spine specific protein 
Homer-3 and also impaired glutamatergic signaling were implicated in the pathophysiology of 
SCA1 by us and by others (Ingram et al., 2016; Ruegsegger et al., 2016; Serra et al., 2004). 
Therefore, the appearance of significant deficits in mitochondria-associated proteins at an age 
coinciding with the onset of symptoms suggested that in addition to early synaptic deficits, 
mitochondrial impairments are also important contributors to the progression of SCA1. To further 
understand the significance of these mitochondrial alterations to SCA1 pathology, we specifically 
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examined mitochondrial morphology and function, which revealed an age-dependent 
morphological and functional impairment in the activities of the mitochondrial ETC and ATPase 
complexes that was associated with oxidative damage. 
There is considerable evidence linking mitochondrial dysfunction, impaired energy metabolism 
and oxidative stress to the pathophysiology of NDs (Lin and Beal, 2006). Deﬁcits in 
mitochondrial function have been strongly implicated in ALS, AD, PD, HD, hereditary spastic 
paraplegia, Friedreich’s ataxia, and Charcot-Marie-Tooth disease (Allen et al., 2015; DiMauro 
and Schon, 2008; Ruffoli et al., 2015; Tatsuta and Langer, 2008). Besides the involvement of 
mitochondria in neuronal development and energy production, mitochondria are also involved in 
a plethora of essential neuron specific processes such as calcium homeostasis, maintenance of 
membrane potential, axonal and dendritic transport, and the release, uptake and reuse of 
neurotransmitters in the synapses. In the context of PolyQ disorders, studies on HD animal and 
cultured cell models have linked defective mitochondrial bioenergetics to HD pathogenesis. In 
HD patients, reductions in the activities of the mitochondrial ETC complexes II, III and IV have 
been observed in the postmortem brain (Brennan et al., 1985; Browne et al., 1997; Gu et al., 
1996). Similar observations involving dysfunctional respiratory chain complexes and increased 
oxidative stress has been made in the pathology associated with the SCA2, SCA3, and SCA12 
forms of spastic paraplegia (Simon et al., 2007; Wang et al., 2011; Yu et al., 2009). In the case 
of SCA1, mutant ATXN1 was shown to bind and impair the function of HMGB1, a DNA damage 
repair protein which was also implicated in mitochondrial DNA damage repair, thereby indirectly 
linking mitochondrial DNA damage to SCA1 disease progression (Ito et al., 2015). Consistent 
with this observation, we found a significant increase in the oxidative DNA damage biomarker; 8-
OHdG in an age-dependent manner, coinciding with the symptomatic phase of the disease. 
Further, we found considerable reduction in activities of ETC complexes paralleling the 
appearance of increased 8-OHdG immunoreactivity, suggesting that oxidative damage to the 
mitochondrial DNA might affect the transcription of critical mitochondrial proteins or that the 
damage occurs directly to the proteins. In this regard, our proteomic screen also revealed that a 
significant number of mitochondrial proteins involved in the ETC complexes and the ATP 
synthase were downregulated in mutant PCs, thereby affecting bioenergetics and proper 
mitochondrial functioning. Additionally, it is well accepted that calcium signaling is impaired in 
SCA1, SCA2 and SCA3 (Brown and Loew, 2012; Halbach et al., 2016; Kasumu et al., 2012; 
Pellistri et al., 2013) and as mitochondria are the second most important calcium storage 
organelle, improper mitochondrial functioning can negatively impact calcium homeostasis and 
neuronal transmission (Wang et al., 2015). 
16 
 
As ETC activity governs the synthesis of ATP, deficits in ETC complexes would inevitably affect 
those metabolic processes that require energy. Metabolic deficits and the loss of body weight at 
early stages of the disease are the most common symptoms observed in SCA1 patients (Mahler 
et al., 2014) as well as in SCA1 mouse models (Jafar-Nejad et al., 2011; Watase et al., 2002). 
Another striking feature of metabolic alteration specifically observed in the cerebellum and brain 
stem of SCA1 patients is a decline in total NAA (N-acetylaspartate + N-acetylglutamate levels 
with a concomitant increase in total levels of creatine, myoinositol and glutamine. This reduction 
in total NAA levels directly correlates with SCA1 patients’ ataxia scores and similar changes 
have also been observed in SCA1 mouse models. Notably, these changes have been 
demonstrated to be dependent on the expression of mutant ATXN1 protein and its deletion in 
conditional SCA1 models rescues those deficits (Emir et al., 2013; Guerrini et al., 2004; Oz et 
al., 2010). Interestingly, N-acetylaspartate (NAA) is synthesized by mitochondria and is a 
neuron-specific metabolite. The reduction in NAA levels is a direct indicator of disturbances in 
ATP production, neuronal injury and compromised neuronal viability (Moffett et al., 2013; 
Signoretti et al., 2008). Moreover, the relationship of mitochondrial NAA synthesis with oxygen 
consumption and ATP production hints at reduced NAA levels in SCA1 patients and mouse 
models as reflecting suboptimal mitochondrial energy production. In this regard our finding that 
mutant Sca1154Q/2Q PCs exhibit mitochondrial dysfunction, mainly involving reduced activities of 
ETC complexes, provides a framework for accounting for the previously observed changes in 
total NAA levels as being due to impaired energy production in mutant PCs. 
Over the past few years, mitochondria have become a therapeutic target in NDs and one 
potential therapeutic agent is MitoQ. It consists of a ubiquinone moiety linked to a positively 
charged lipophilic cation that allows its selective and extensive accumulation within mitochondria 
driven by the high mitochondrial membrane potential (Smith and Murphy, 2010). Within 
mitochondria, the ubiquinone moiety is rapidly reduced to the active antioxidant form ubiquinol 
by respiratory complex II (James et al., 2007). The protective effect of MitoQ against oxidative 
stress has been shown in a number of neurodegenerative mouse models such as for ALS 
(Miquel et al., 2014), AD (McManus et al., 2011) and PD (Ghosh et al., 2010). Therefore, we 
examined whether MitoQ administration would be beneficial in improving mitochondrial deficits 
and preventing ataxia-like pathology in mouse model of SCA1. MitoQ treatment reversed 
mitochondrial morphological alterations and restored activities of ETC complexes. To examine 
whether the mitochondrial protection conferred by MitoQ was sufficient to prevent the 
emergence of SCA1 pathology in vivo, we treated young Sca1154Q/2Q mice, which do not exhibit 
mitochondrial deficits with MitoQ for 110 days and evaluated the effect on the appearance of 
SCA1-associated symptoms. Notably, MitoQ treatment slowed down the development of motor 
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incoordination and the appearance of gait deficits. Moreover, MitoQ administration significantly 
reduced PC dendrite and PC degeneration. Remarkably, treatment of Sca1154Q/2Q mice with 
MitoQ for short periods of time when mitochondrial impairments and behavioral deficits were 
already present, revealed a substantial improvement of mitochondrial function and reduced PC 
loss. This short treatment regime of MitoQ is clinically feasible and, as MitoQ has been given to 
PD patients safely for up to a year (Snow et al., 2010), could be administered to patients after 
their diagnosis with SCA1.  
The precise pathways which lead to the observed deficits in mitochondrial bioenergetics remain 
uncertain, however, it is likely that mutant ATXN1 could negatively influence the transcription of 
multiple genes encoding important mitochondrial proteins, which in turn impair critical oxidative 
and energy-associated metabolic pathways. Moreover, higher ROS levels and mutant ATXN1-
linked reduction of the high-mobility group box 1 protein (HMGB1) in mitochondria could lead to 
accumulation of mitochondrial DNA damage, which might synergistically contribute to suboptimal 
mitochondrial functioning. Further, our previous study had implicated early synaptic deficits 
involving the reduced expression of calcium binding proteins and PC spine-specific protein 
Homer-3 in regulating SCA1 pathophysiology (Ruegsegger et al., 2016). Early impairment in PC 
specific calcium homeostasis could lead to a mitochondrial calcium overload. It has been 
previously shown that mitochondrial calcium overload causes mitochondrial fragmentation and 
oxidative stress (Peng and Jou, 2010). In this regard, it will be interesting in the future to 
examine whether synaptic deficits and impaired calcium homeostasis also influences 
mitochondrial functioning or whether these cellular dysfunctions are independent events in 
SCA1. Taken together, our work reveals an important role for mitochondria dysfunction in SCA1 
progression and provides evidence for the beneficial use of the mitochondria-targeted 
antioxidant MitoQ in SCA1. 
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Figure 1. Mass spectrometry analysis identifies mitochondrial impairments in mutant 
Sca1154Q/2Q PCs 
(A) Using LCM, PCs were isolated and analyzed by MS. Of the 340 proteins reliably detected 
from two separate experiments, nearly 41% of the proteins displayed consistent ≥ 2 fold 
alteration alterations in expression levels in P100, Sca1154Q/2Q vs. WT PCs. Only proteins with a 
minimum PMSS of 30 and 3 or more unique peptides and detected in two separate experiments 
were analyzed. n = 4 mice per genotype per experiment. 
(B) PANTHER overrepresentation analysis for pathways changed at P100 in Sca1154Q/2Q vs. WT 
PCs presenting enrichment for ATP synthesis and synaptic vesicle trafficking proteins. Protein 
classes which were significantly altered involved anion channels and members of the 
oxidoreductase family of proteins.  
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(C) 33% of the changed proteins in Sca1154Q/2Q PC proteome were downregulated at P100 and 
grouped according to protein classes after PANTHER analysis.  
(D and E) Analysis of the PC proteome at P100. Strongest alterations in Sca1154Q/2Q PC 
proteome were for ATP synthesis (D) and for proteins functioning as oxidoreductase, involving 
the use utilization of NADP or NAD+ as cofactors for catalyzing the transfer of electrons from one 
molecule, electron donor (reductant), to electron acceptor (oxidant) (E). Data plotted by PMSS 
score (only proteins reproducibly altered in 2 experiments were analyzed, PMSS values plotted 
for one experiment). 
Figure 2. PCs of symptomatic Sca1154Q/2Q mice show altered mitochondrial morphology  
(A) Immunolabeling for HSP60 (Mitochondrial marker) and Calbindin (PC maker) revealing an 
increased number of vesicular (spherical) shaped mitochondria in PCs of Sca1154Q/2Q mice at 
symptomatic stages P110 and P150, but not earlier.  
(B) Left: Histogram for the mitochondrial distribution according to their sphericity value at P110. 
Right: Quantitative analysis (Q.A.) representing the proportion of mitochondria falling below or 
above a critical sphericity value (median of WT mice). n = 4 mice per genotype at P60 and P150, 
5 mice per genotype at P110 (8-12 cells per individual mouse). 
(C) SBF-SEM images rendered for mitochondria demonstrating that mitochondria of Sca1154Q/2Q 
PCs were shorter in length.  
(D) Left: Histogram for the mitochondrial distribution according to their lengths. Right: Q.A. 
representing the proportion of mitochondria falling below or above a critical length (median of 
WT mice). n = 8 cells (250 mitochondria each) per genotype (3 mice each). Unpaired t test 
*p<0.05, **p<0.01, ***p<0.001. Scale bar: 10µm. 
Figure 3. Reduced ETC complex I, II, IV and V activities in PCs of symptomatic Sca1154Q/2Q 
mice 
Colorimetric assay in fresh thin cerebellar sections revealing decreased ETC complex I (A), II 
(B), IV (C) and V (D) staining intensities in PC somas of P110, Sca1154Q/2Q mice. ML: Molecular 
layer, PL: Purkinje cell layer, GL: Granule cell layer. Q.A. is presented as box with whiskers 
(Turkey). n = 43-80 sections (average) per genotype and assay (3 mice per genotype for 
Complex I and V, 4 mice per genotype for Complex II and IV). Unpaired t test *p<0.05, **p<0.01, 
***p<0.001. Scale bar: 50µm. 
Figure 4. Oxidative stress correlates with mitochondrial impairments in Sca1154Q/2Q mice 
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(A) Induction of oxidative stress by 3d chromium(VI) treatment led to an increased number of 
vesicular shaped mitochondria in WT PCs.  
(B) ETC complex I and IV staining intensities were reduced after a 3d chromium(VI) treatment. ). 
n = 30-50 sections (average) per genotype and assay (2 mice per genotype) 
(C) Immunolabeling for 8-OHdG and Calbindin indicating increased oxidative stress in 
Sca1154Q/2Q PCs at symptomatic stages P110, but not earlier (P60).  
(D) Q.A. is presented as box with whiskers (Turkey). n = 9-12 sections (average) per age and 
genotype (4 mice each). Unpaired t test *p<0.05, **p<0.01, ***p<0.001. Scale bars: (A) = 10µm, 
(B) = 50µm and (C) = 20µm. 
Figure 5. MitoQ treatment ameliorates mitochondrial morphological impairments in PCs 
of Sca1154Q/2Q mice 
(A) Immunolabeling for HSP60 and Calbindin at P150 demonstrating numerous vesicular 
shaped mitochondria (arrowheads) in Sca1154Q/2Q control PCs. “Long term” MitoQ treatment from 
P40-150 restored mitochondrial morphology in PCs of P150, Sca1154Q/2Q mice and did not have 
an effect on P150, WT animals.  
(B) Q.A. representing the proportion of mitochondria falling below or above a critical sphericity 
value (median of WT control mice). n = 4 mice [WT control], 3 mice [150, WT MitoQ trt P40-150], 
4 mice [Sca1154Q/2Q control], 4 mice [Sca1154Q/2Q MitoQ trt P40-150] (6-12 cells per individual 
mouse).  
(C) HSP60 and Calbindin immunolabeling at P110 presenting numerous vesicular shaped 
mitochondria (arrowheads) in PCs of SCA1154Q/2Q control mice. “Short term” MitoQ treatment 
from P90-P110 restored mitochondrial morphology in P110, Sca1154Q/2Q PCs.  
(D) Q.A. presenting the proportion of mitochondria falling below or above a critical sphericity 
value (median of WT mice). n = 5 mice [WT control], 5 mice [Sca1154Q/2Q control] and 3 mice 
[Sca1154Q/2Q MitoQ trt P90-110] (6-12 cells per individual mouse).  
(E) SBF-SEM images rendered for mitochondria demonstrating that mitochondria of Sca1154Q/2Q 
MitoQ trt P90-110 and WT PCs had similar lengths.  
(F) Left: Histogram for the mitochondrial distribution according to their lengths. Right: Q.A. 
representing the proportion of mitochondria falling below or above a critical length (median of 
WT mice). n = 8 cells (250 mitochondria each) per genotype (3 mice each). One-way ANOVA 
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with post hoc Bonferroni’s test (B and D), unpaired t test (F) *p<0.05, **p<0.01, ***p<0.001. 
Scale bar: 10µm. 
Figure 6. Long term MitoQ treatment of Sca1154Q/2Q mice from P40-150 restores 
functionality of ETC complexes I, II, IV and V  
Colorimetric assay for complex I (A), II (B), IV (C) and V (D) activities in fresh thin cerebellar 
sections displayed significant reduced staining intensities in PCs of P150, SCA1154Q/2Q mice 
which were restored after MitoQ administration from P40-150. Q.A. is presented as box with 
whiskers (Turkey). n = 40-78 sections (average) per group (4 mice [WT control], 3 mice [WT 
MitoQ trt P40-150], 4 mice [Sca1154Q/2Q control] and 4 mice [Sca1154Q/2Q MitoQ trt P40-150]). 
One-way ANOVA with post hoc Bonferroni’s test *p<0.05, **p<0.01, ***p<0.001. Scale bar: 
20µm. 
Figure 7. MitoQ treatment ameliorates motor coordination and PC neuropathology of 
symptomatic Sca1154Q/2Q mice 
(A) Rotarod performance was measured for WT and Sca1154Q/2Q mice that were either untreated 
(control) or treated with MitoQ from P40-150 (MitoQ trt P40-150). Compared to WT control mice, 
Sca1154Q/2Q control animals exhibited significant differences in motor coordination from P110 on, 
whereas Sca1154Q/2Q MitoQ trt P40-150 mice did not display significant alterations until P150. 
MitoQ treatment did not have a significant effect on WT animals. n = 9 mice [WT control], 6 mice 
[WT MitoQ trt P40-150], 14 mice [Sca1154Q/2Q control] and 9 mice [Sca1154Q/2Q MitoQ trt P40-150].  
(B) Hind-limb clasping performance is blotted via clasping score criteria (The higher score 
corresponds to worse phenotype). Compared to Sca1154Q/2Q control, Sca1154Q/2Q MitoQ trt P40-
150 mice demonstrated an improved score at P110 (left) and P150 (right). MitoQ treatment did 
not have an effect on WT mice. n = 6 mice [WT control], 6 mice [WT MitoQ trt P40-150], 6 mice 
[Sca1154Q/2Q control] and 9 mice [Sca1154Q/2Q MitoQ trt P40-150].  
(C) Quantified Calbindin intensities, averaged and blotted from the perikaryon center over the 
dendrites, presenting decreased levels in Sca1154Q/2Q control compared to WT control mice, 
which were restored after MitoQ treatment from P40-150 (left) and P90-110 (right).  
(D) PC number over 315 µm was quantified in lobule V revealing reduced PCs in Sca1154Q/2Q 
control mice. Both, MitoQ administration from P40-150 (left) and P90-110 (right) prevented PC 
loss in Sca1154Q/2Q animals. n = 12-30 section per group (P150: 5 mice [WT control], 3 mice [WT 
MitoQ trt P40-150], 5 mice [Sca1154Q/2Q control] and 4 mice [Sca1154Q/2Q MitoQ trt P40-150]; 
P110: 7 mice [WT control], 5 mice [Sca1154Q/2Q control] and 3 mice [Sca1154Q/2Q MitoQ trt P90-
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110] (C and D). Two-way ANOVA with post hoc Bonferroni’s test (A), One-way ANOVA with post 
hoc Bonferroni’s test for (B and D) *p<0.05, **p<0.01, ***p<0.001. 
 
Suppl. Figure 1. Schematic representation of PC mitochondrial isosurface. 
A representative image showing immunohistomchemical labeling of mitochondria in P110, WT 
and Sca1154Q/2Q PCs and its corresponding isosurface buildup using Imaris 7.6. Scale bar: 10µm. 
Suppl. Figure 2. Short term MitoQ treatment from P90-110 improves ETC complex 
activities Sca1154Q/2Q PCs and reduces levels of oxidative stress marker 8OHdG 
Colorimetric assay for ETC complex I (A), II (B), IV (C) and IV (D) activities displays reduced 
intensity levels in PCs of Sca1154Q/2Q control mice and that MitoQ administration from P90-100 
reverses this effect. Q.A. is presented as box with whiskers (Turkey). n = 34-80 sections 
(average) per group (4 mice [WT control], 4 mice [Sca1154Q/2Q control] and 3 mice [Sca1154Q/2Q 
MitoQ trt P90-110] for Complex II and IV; 3 mice [WT control], 3 mice [Sca1154Q/2Q control] and 3 
mice [Sca1154Q/2Q MitoQ trt P90-110] for Complex I and V.  
(E) P110, Sca1154Q/2Q control mice display elevated 8-OHdG levels which is restored after the 
treatment with MitoQ from P90-110. Q.A. is presented as box with whiskers (Turkey). n = 9-12 
sections (average) per group (4 mice [WT control], 4 mice [Sca1154Q/2Q control] and 3 mice 
[Sca1154Q/2Q MitoQ trt P90-110]). One-way ANOVA with post hoc Bonferroni’s test *p<0.05, 
**p<0.01, ***p<0.001.  Scale bars: (A-D) = 50 µm and (E) = 20µm. 
 
Table S1 related to main Figure 1. 
Complete list of proteins identified by MS which were altered in mutant PCs from Sca1154Q/2Q 
mice compared to WT mice. 
 
Highlights 
 Morphological and functional mitochondrial alterations in SCA1 Purkinje cells 
 Mitochondrial impairments coincides with elevated levels of oxidative stress  
 Administration of antioxidant MitoQ to SCA1 mice ameliorates mitochondrial deficits 
 Restoring mitochondrial function improves motor coordination and neuropathology  
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